Highly efficient directed differentiation of human induced pluripotent stem cells into cardiomyocytes.
Highly efficient directed differentiation of human induced pluripotent stem cells into cardiomyocytes.
复制标题
DOI：
10.1007/978-1-62703-348-0_12
复制
发表时间：
2013-01-01
期刊：
影响因子：
--
通讯作者：
Zambidis, Elias T
中科院分区：
文献类型：
--
作者：
Burridge, Paul W;Zambidis, Elias T
人类诱导多能干细胞（hiPSC）衍生的心肌细胞是用于患者特异性心脏毒性药物测试、药物发现、疾病建模和再生医学的新细胞来源。我们描述了一种多功能且具有成本效益的体外心脏分化方案，该方案对各种各样的hiPSC和人胚胎干细胞（hESC）系有效。这种高度优化的方案在不到9天的时间内产生收缩的人胚状体（hEB），总效率接近94.7±2.4%，并且最大限度地减少了不同hiPSC和hESC系之间常见的心脏分化差异。使用这些方法获得的收缩hEB含有高比例的纯功能心肌细胞，高度可重复性的电生理特征，以及对已知心脏活性药物的药理学反应性。
Human-induced pluripotent stem cell (hiPSC)-derived cardiomyocytes are a novel source of cells for patient-specific cardiotoxicity drug testing, drug discovery, disease modeling, and regenerative medicine. We describe a versatile and cost-effective protocol for in vitro cardiac differentiation that is effective for a wide variety of hiPSC and human embryonic stem cell (hESC) lines. This highly optimized protocol produces contracting human embryoid bodies (hEB) with a near total efficiency of 94.7 ± 2.4% in less than 9 days, and minimizes the variability in cardiac differentiation commonly observed between various hiPSC and hESC lines. The contracting hEB derived using these methods contain high percentages of pure functional cardiomyocytes, highly reproducible electrophysiological profiles, and pharmacologic responsiveness to known cardioactive drugs.